Table 5.

Management of patients attending outpatient clinic with mildly active inflammatory bowel disease in the scenario of the asymptomatic severe acute respiratory syndrome coronavirus 2 infection or confirmed or suspected coronavirus disease 2019 [11,15,4,161,162].

	Management
Asymptomatic infection or with SARS-CoV-2	(1) Budesonide, aminosalycilates, antibiotics, and topical therapy may be used if needed; (2) Holds immunomodulators, tofacitinib, and biologics for 2 wk; (3) Taper withdraw corticosteroids (prednisone < 20 mg/d); and (4) Monitoring for 2 wk for COVID-19 to present.
Mild COVID-19	(1) Budesonide, aminosalycilates, antibiotics, and topical therapy may be used if needed; (2) Hold immunomodulators, tofacitinib, and biologics for 2 wk; (3) Taper or withdraw systemic corticosteroids); and (4) Monitoring for 2 wk for COVID-19 symptoms to disappear.
COVID-19 with pulmonary unit involvement without SHS	(1) Budesonide, aminosalycilates, antibiotics, and topical therapy may be used if necessary; (2) Hold immunomodulators, tofacitinib, and biologics for at least 2 wk or COVID-19 resolves; and (3) Taper or withdraw systemic corticosteroids.